Catch up on the essentials
- The revision sits above consensus, suggesting Engel models faster EPS growth than the Street, though the size of the change is small enough to qualify as routine estimate maintenance rather than a directional call.
- Coverage skews positive: 1 Strong Buy, 21 Buy, 8 Hold, and 1 Sell rating, with an average 12-month price target of $501.98 against a $427.64 print on October 13 and an average "Moderate Buy" consensus [Daily Political, Oct 13, 2026].
- Intuitive Surgical's next scheduled quarterly release, where procedure growth and margin trajectory will be disclosed, is the next verifiable checkpoint against Engel's above-consensus FY2027 path.
Selected from this article · 2026-10-13
Read on for the full pictureA modest, single-analyst revision
Erste Group Bank analyst H. Engel raised the FY2027 EPS estimate for Intuitive Surgical (NASDAQ:ISRG) to $10.09 from $10.06 in a note issued to clients on October 8, a $0.03 upward tick against a current full-year consensus of $8.87 [MarketBeat, Oct 13, 2026; Ticker Report, Oct 13, 2026]. The revision sits above consensus, suggesting Engel models faster EPS growth than the Street, though the size of the change is small enough to qualify as routine estimate maintenance rather than a directional call.
Quarterly results frame the baseline
Intuitive Surgical last reported quarterly results on July 16, posting EPS of $2.80 versus a $2.48 consensus and revenue of $2.89 billion, up 18.4% year over year, with a 28.45% net margin and 16.91% return on equity [Daily Political, Oct 13, 2026; MarketBeat, Oct 13, 2026]. Those figures anchor FY2027 projections: scaling off a $2.80 quarter does not mechanically reach $10.09 without a meaningful acceleration in procedure volumes or operating leverage.
Street sentiment leans constructive, with one trim
Coverage skews positive: 1 Strong Buy, 21 Buy, 8 Hold, and 1 Sell rating, with an average 12-month price target of $501.98 against a $427.64 print on October 13 and an average "Moderate Buy" consensus [Daily Political, Oct 13, 2026]. BTIG cut its target to $454 from $469, a counter-signal that the Street is not uniformly bullish, while insider sales (including EVP Mark Brosius selling 77 shares at $375.57 on August 21) show continued selling activity, without a stated rationale for the trades [Daily Political, Oct 13, 2026].
Related industries and supply products
Industry / product or service | Evidence level | Event connection | Verification signal | Main risk |
|---|---|---|---|---|
Surgical robotics components and instruments | Research watchlist | Higher FY2027 EPS assumptions imply sustained da Vinci procedure growth | Watch Intuitive Surgical quarterly procedure growth disclosures | Margin compression if procedure mix shifts |
No procurement has been confirmed; the FY2027 EPS revision is an analyst note, not a purchase signal. Intuitive Surgical's next scheduled quarterly release, where procedure growth and margin trajectory will be disclosed, is the next verifiable checkpoint against Engel's above-consensus FY2027 path.
Share this article
